Substantial Changes to Protocol: 1. Within the inclusion criteria, the washout period for prior statin use at trial entry was amended from 2 months to 28 days. The purpose of this update was to provide more flexibility for low risk patients already receiving statin treatment who wish to enter the study. This was discussed by the study Investigators/Co-Investigators and is deemed to be clinically appropriate.   2. Within the inclusion criteria, the fasting glucose level requirement of ≤ 5.6mmol/L was removed. This was discussed by the study Investigators/Co-Investigators and was deemed to be clinically appropriate. The requirement for fasting glucose was removed as it was agreed it would unnecessarily exclude patients. The NICE guidelines for the use of stains in individuals with diabetes were consulted as part of these discussions, and it was agreed that the benefit of statins use outweighed the small risk of developing Diabetes Mellitus 2 over a 10yr period. In the SPECTRE cohort of Castration Resistant Prostate Cancer patients with life expectancy of <2years the risk of causing Diabetes Mellitus 2 with 6 weeks of statin is negligible. The protocol was also updated to include guidance that the study patient’s GPs should be contacted in the event of fasting glucose > 7mmol/L, to ensure it is monitored/treated as per normal practice. 3. The timing of the first tumour biopsy was updated from being prior to atorvastatin start to being +/- 7 days of atorvastatin start. The purpose of this change wass to provide more flexibility for scheduling the biopsies around the patient's clinic attendance without compromising the validity of the samples/data. Non-substantial Changes: 1. The contact details of several study team members were updated.

Protcol Updates: 1. Update to the inclusion requirements for proven prostate cancer, to bring SPECTRE in line with many other clinical studies in progressing prostate cancer with the use of histologic, cytologic or biochemical parameters as confirmation of the presence of prostate cancer. 2. Protocol inclusion criteria updated to include patients who have been treated with abiraterone acetate or enzalutamide. 3. Protocol inclusion criteria updated to allow ongoing castration with abiraterone or enzalutamide. 4. Corection made to typographical error at inclusion level of haemoglobin and platelets 5. Clarification added that the tumour biopsies are an optional component of the study. 6. Exclusion criteria updated to allow prior chemotherapy and prior second-line androgen deprivation therapy 7. Guidance added to the Safety Reporting section regarding the reporting of pregnancies. 8. The Patient Information sheet/consent form was updated with guidance on possible side effects for patients continuing on abiraterone during SPECTRE study treatment.

Protcol Updates: This amendment was submitted 06-Feb-2020 1. Update to study team contact details 2. The study objective 'Change in adrenal steroid DHEA (dehydroepiandrosterone) levels' was amended from being a secondary objective to an exploratory objective 3. Typographical corrections made to the Safety Reporting section